A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

Summary

This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.

Timeline

Start

2025-10-22

Primary completion

2027-12

Completion

2028-12

Drugs

Indications